Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy (AIPAC-003)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05747794 |
|
Recruitment Status :
Recruiting
First Posted : February 28, 2023
Last Update Posted : June 2, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The goal of this clinical trial is to compare the safety and efficacy of eftilagimod alpha (efti) in combination with paclitaxel standard of care chemotherapy in participants with metastatic breast cancer.
The main questions it aims to answer are:
- What is the optimal biological dose (OBD) of efti in combination with weekly paclitaxel chemotherapy?
- Can efti combined with weekly paclitaxel chemotherapy prolong overall survival in participants with metastatic breast cancer if compared to weekly paclitaxel chemotherapy alone.
In the first component of the trial (phase 2, lead-in) researchers will compare two groups (different dose levels of efti in combination with standard chemotherapy) to see if the treatment is safe and well tolerated and evaluate which is the optimal biological dose. In the second component of the trial (phase 3) researchers will assess if the treatment of metastatic breast cancer with the optimal biological dose of efti in combination with paclitaxel is superior compared to chemotherapy alone (placebo-controlled).
The treatment concept of each trial component consists of a chemo-immunotherapy phase followed by an immunotherapy phase. In the first phase participants will be treated with efti plus paclitaxel chemotherapy or placebo plus paclitaxel chemotherapy. After completion of the chemotherapy per standard of care, participants will be treated with the study agent alone.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Breast Carcinoma | Biological: eftilagimod alpha Drug: Paclitaxel Other: placebo | Phase 2 Phase 3 |
The AIPAC-003 trial consists of an open-label dose optimization lead-in component followed by a double-blinded, randomized, placebo-controlled phase 3 component.
The main objectives of the dose optimization lead-in (phase 2) are to evaluate and compare the safety and tolerability of 2 different dose levels of efti (30mg and 90mg) combined with paclitaxel, and to define the optimal biological dose (OBD) of efti in combination with weekly paclitaxel for the phase 3 part of the trial. Recruitment to the dose-optimization lead-in will be considered complete when 29 participants per cohort are randomized and considered evaluable for OBD analysis.
The main objective of the phase 3 is to demonstrate that overall survival (OS) is superior in participants treated with efti combined with weekly paclitaxel compared to weekly paclitaxel plus placebo. Approximately 771 participants will be randomized 2:1 to Arm A (active arm): paclitaxel + efti at OBD and Arm B (control arm): paclitaxel + placebo. The exact patient population will be defined after determination of the OBD.
The duration of the trial will be approximately 24 months for the dose optimization lead-in component and 60 months for the phase 3 component. The phase 3 will start prior to the completion of the phase 2 (once the OBD has been defined).
It is planned to conduct the trial at up to 20 sites in up to 4 countries across North America and Europe for the lead-in and at up to 150 sites in up to 25 countries across North America, Europe, Latin America and the Asian Pacific region for the phase 3.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 849 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | This trial consists of an open-label dose optimization lead-in component (phase 2) followed by a double-blinded, randomized, placebo-controlled phase 3 component. |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | AIPAC-003 (Active Immunotherapy and PAClitaxel): A Randomized, Double-blind, Placebo-controlled Phase 3 Trial Testing Eftilagimod Alpha (Soluble LAG-3) in HER2-neg/Low Metastatic Breast Cancer Patients Receiving Paclitaxel, Following an Open-label Dose Optimization |
| Actual Study Start Date : | May 22, 2023 |
| Estimated Primary Completion Date : | October 31, 2026 |
| Estimated Study Completion Date : | July 31, 2027 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: open label lead-in (phase 2): eftilagimod alpha 30mg + paclitaxel
eftilagimod alpha 30mg s.c. + 80mg/m^2 paclitaxel i.v. (same-day administration): The trial consists of a chemo-immunotherapy (chemo-IO) phase followed by an immunotherapy (IO)-phase. The chemo-IO phase consists of a planned 6 cycles of 4 weeks (28 days each) that may be longer or shorter depending on chemo tolerance. The IO-phase is planned to follow the chemo-IO phase. A maximum of 13 cycles (approx. 12 months) of treatment is planned.
|
Biological: eftilagimod alpha
APC activator, MHC II agonist
Other Names:
Drug: Paclitaxel paclitaxel will be given as standard of care (chemotherapy) |
|
Experimental: open label lead-in (phase 2): eftilagimod alpha 90mg + paclitaxel
eftilagimod alpha 90mg s.c. + 80mg/m^2 paclitaxel i.v. (same-day administration): The trial consists of a chemo-immunotherapy (chemo-IO) phase followed by an immunotherapy (IO)-phase. The chemo-IO phase consists of a planned 6 cycles of 4 weeks (28 days each) that may be longer or shorter depending on chemo tolerance. The IO-phase is planned to follow the chemo-IO phase. A maximum of 13 cycles (approx. 12 months) of treatment is planned.
|
Biological: eftilagimod alpha
APC activator, MHC II agonist
Other Names:
Drug: Paclitaxel paclitaxel will be given as standard of care (chemotherapy) |
|
Experimental: Phase 3: eftilagimod alpha + paclitaxel
eftilagimod alpha s.c. (OBD) + 80mg/m^2 paclitaxel i.v. (same-day administration): The trial consists of a chemo-immunotherapy (chemo-IO) phase followed by an immunotherapy (IO)-phase. The chemo-IO phase consists of a planned 6 cycles of 4 weeks (28 days each) that may be longer or shorter depending on chemo tolerance. The IO-phase is planned to follow the chemo-IO phase. A maximum of 13 cycles (approx. 12 months) of treatment is planned.
|
Biological: eftilagimod alpha
APC activator, MHC II agonist
Other Names:
Drug: Paclitaxel paclitaxel will be given as standard of care (chemotherapy) |
|
Placebo Comparator: Phase 3: placebo + paclitaxel
placebo s.c. + 80mg/m^2 paclitaxel i.v. (same-day administration): The trial consists of a chemo-immunotherapy (chemo-IO) phase followed by an immunotherapy (IO)-phase. The chemo-IO phase consists of a planned 6 cycles of 4 weeks (28 days each) that may be longer or shorter depending on chemo tolerance. The IO-phase is planned to follow the chemo-IO phase. A maximum of 13 cycles (approx. 12 months) of treatment is planned.
|
Drug: Paclitaxel
paclitaxel will be given as standard of care (chemotherapy) Other: placebo placebo matching eftilagimod alpha
Other Name: placebo matching eftilagimod alpha |
- Determination of Overall survival (OS) [ Time Frame: Until trial end, death, withdrawal of consent or lost to follow-up, assessed up to 60 months ]
- Determination of the Optimal Biological Dose (OBD) [ Time Frame: Up to 15 months ]
- Frequency of adverse events (AEs) [ Time Frame: Up to 15 months ]
- Severity of adverse events (AEs) [ Time Frame: Up to 15 months ]
- Duration of adverse events (AEs) [ Time Frame: Up to 15 months ]
- Occurrence of dose-limiting toxicities (DLTs) [ Time Frame: Up to 15 months ]
- Occurrence of clinically relevant abnormalities in vital signs [ Time Frame: Up to 15 months ]
- Occurrence of clinically relevant abnormalities in physical examinations [ Time Frame: Up to 15 months ]
- Occurrence of clinically relevant abnormalities in 12-lead ECGs [ Time Frame: Up to 15 months ]
- Occurrence of clinically relevant abnormalities in safety laboratory assessments [ Time Frame: Up to 15 months ]
- Determination of Progression Free Survival (PFS), based on RECIST, v1.1 [ Time Frame: Until occurrence of progressive disease, or the start of any further next line anticancer treatment, or until the end of the trial for any other reason, assessed up to 60 months ]
- Evaluation of Objective Response Rate (ORR) based on RECIST v1.1 [ Time Frame: Until occurrence of progressive disease, or the start of any further next line anticancer treatment, or until the end of the trial for any other reason, assessed up to 60 months ]
- Changes from baseline in quality of life (QOL) as assessed by questionnaire of European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 [ Time Frame: Up to 13 months ]EORTC QLQ-C30 is a 30-item self-administered cancer specific questionnaire designed to measure QOL in the cancer population
- PK parameter: area under the curve (AUC) (dose optimization lead-in only) [ Time Frame: Up to 4 months ]
- PK parameter: peak serum concentration (Cmax) (dose optimization lead-in only) [ Time Frame: Up to 4 months ]
- PK parameter: time to reach Cmax (tmax) (dose optimization lead-in only) [ Time Frame: Up to 4 months ]
- PK parameter: systemic clearance (CL) (dose optimization lead-in only) [ Time Frame: Up to 4 months ]
- PK parameter: elimination half-life (t1/2) (dose optimization lead-in only) [ Time Frame: Up to 4 months ]
- PK parameter: volume of distribution (VD) (dose optimization lead-in only) [ Time Frame: Up to 4 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Metastatic HR+ positive (estrogen receptor positive and/or progesterone receptor positive) or hormone receptor negative (HR˗), and HER2-neg breast adenocarcinoma, histologically proven by biopsy on the last available tumor tissue
- Participants with HR+ metastatic breast cancer (MBC) who progressed on or after ≥1 line of endocrine based therapy and are indicated to receive chemotherapy for metastatic disease
- Participants with HR˗ MBC (i.e. triple-negative breast cancer [TNBC]) who are indicated to receive paclitaxel chemotherapy without PD 1/PD-L1 therapy in the 1st line setting for metastatic disease
- ECOG performance status 0-1
- Expected survival longer than three months
Exclusion Criteria:
- Prior chemotherapy for metastatic breast adenocarcinoma
- Participants with HR+ MBC who have received <1 line of ET based therapy in the metastatic setting
- Participants with HR+ MBC who are not primary or secondary resistant to ET-based therapy and would be candidates to ET based therapy as per applicable treatment guidelines
- TNBC participants who are candidates for PD-1/PD-L1 therapy in combination with chemotherapy
- Disease-free interval of less than twelve months from the last dose of adjuvant chemotherapy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05747794
| Contact: Frédéric Triebel, Prof. MD | +49 30 88716843 | enquiries@immutep.com |
| United States, California | |
| The Oncology Institute | Recruiting |
| Whittier, California, United States, 90602 | |
| Contact: Omkar Marathe, MD | |
| United States, South Carolina | |
| Carolina Blood and Cancer Care Associates | Recruiting |
| Rock Hill, South Carolina, United States, 29723 | |
| Contact: Sashi Naidu, MD | |
| United States, Texas | |
| Oncology Consultants | Recruiting |
| Houston, Texas, United States, 77024 | |
| Contact: Julio Peguero, MD | |
| Belgium | |
| Cliniques Universitaires Saint-Luc | Recruiting |
| Brussel, Belgium, 1200 | |
| Contact: Francois Duhoux, MD | |
| Grand Hopital de Charleroi - Hopital Notre Dame | Recruiting |
| Charleroi, Belgium, 6000 | |
| Contact: Jean-Luc Canon, MD | |
| Centre Hospitalier de l'Ardenne | Recruiting |
| Libramont, Belgium, 6800 | |
| Contact: Frederic Forget, MD | |
| Responsible Party: | Immutep S.A.S. |
| ClinicalTrials.gov Identifier: | NCT05747794 |
| Other Study ID Numbers: |
AIPAC-003 2022-003323-17 ( EudraCT Number ) |
| First Posted: | February 28, 2023 Key Record Dates |
| Last Update Posted: | June 2, 2023 |
| Last Verified: | June 2023 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Paclitaxel |
Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |